Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Focus Therapeutic Use
- 16 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2017 Planned number of patients changed from 162 to 180.